Mercado global de medicamentos à base de ácidos nucleicos – Tendências do setor e previsão para 2030

Análise e dimensão do mercado de medicamentos à base de ácidos nucleicos

Estão a ser desenvolvidas novas técnicas de tratamento baseadas em medicamentos de ácidos nucleicos. Devido às propriedades únicas que lhes permitem abordar alvos indestrutíveis utilizando pequenas moléculas tradicionais ou produtos biológicos baseados em proteínas/anticorpos, prometem tratar doenças humanas, como malignidades, infeções virais e anomalias genéticas. Os medicamentos de ácidos nucleicos utilizam informações da sequência de nucleótidos para influenciar os processos biológicos das células. Estes medicamentos atuam pela expressão nas células ou pelo controlo de genes, principalmente aqueles com sequências complementares.

A Data Bridge Market Research analisa que o mercado global de medicamentos à base de ácidos nucleicos, que foi de 32,05 milhões de dólares em 2022, deverá atingir os 135,97 milhões de dólares até 2030 e deverá passar por um CAGR de 19,80 % durante o período de previsão. Isto indica que o valor de mercado. “Antisense” domina o segmento de categoria do mercado de medicamentos à base de ácidos nucleicos devido ao aumento das aprovações e lançamentos de medicamentos. Além dos insights sobre cenários de mercado, tais como valor de mercado, taxa de crescimento, segmentação, cobertura geográfica e grandes players, os relatórios de mercado com curadoria da Data Bridge Market Research incluem também análise especializada aprofundada, epidemiologia de pacientes, análise de pipeline, análise de preços, e quadro regulamentar.

Âmbito e segmentação do mercado de medicamentos baseados em ácido nucleico

Market Definition

Target therapeutics based on nucleic acids or closely related chemical substances are known as nucleic acid-based drugs. These medications have the ability to target disorders at the genetic level and prevent disease-causing proteins from being expressed. The major active elements in nucleic acids are oligonucleotides, made via chemical synthesis, and tiny molecules. Nucleic acids are usually thought of as drug transporters, and they can cause undesired biological responses such immune system activation and blood clotting pathway extension. As a result, the advantages of nucleic acid-based pharmaceuticals in possible drug delivery systems for controlled drug releases are the primary rationale for their increased use in the market.            

Nucleic Acid Based Drugs Market Dynamics

Drivers

• Rising incidence of genetic and rare diseases

The increasing prevalence of genetic and rare diseases, such as cystic fibrosis, muscular dystrophy, and various inherited genetic disorders, has created a significant demand for nucleic acid-based therapies. These drugs offer the potential to treat the underlying genetic causes of these diseases, providing hope for patients who previously had limited treatment options.

• Growing investment in research and development

Pharmaceutical companies and biotechnology firms are investing heavily in research and development of nucleic acid-based drugs. This includes antisense oligonucleotides, siRNA, and gene therapies. The promise of these therapies in addressing previously untreatable conditions has spurred increased funding and innovation in the field.

• Advancements in biotechnology and genomics

Ongoing advancements in biotechnology and genomics have led to a better understanding of nucleic acids, including DNA and RNA. This has paved the way for the development of novel nucleic acid-based drugs. The ability to sequence and manipulate nucleic acids has accelerated drug discovery and development in this field.

• Personalized medicine and targeted therapies

Nucleic acid-based drugs can be tailored to an individual's genetic makeup, enabling personalized treatment plans. This approach is gaining prominence as it can lead to more effective and safer treatments, particularly in cancer and rare diseases. Advances in precision medicine are driving the demand for nucleic acid-based therapies. 

Opportunities

• Expansion of rare disease therapies

Nucleic acid-based drugs have shown immense promise in treating rare genetic disorders that were previously untreatable. As more research and development efforts focus on these conditions, there is an opportunity to provide life-changing treatments for patients with rare diseases. This market segment is relatively underserved, creating a significant growth opportunity.

• Advances in gene editing technologies

Advances in gene editing technologies like CRISPR-Cas9 are opening up new possibilities for gene therapies. This technology allows for precise modification of genes, offering opportunities to correct genetic mutations that underlie various diseases. The development and commercialization of gene editing-based nucleic acid therapies present a significant growth avenue. 

Restraints

• High development costs

The research and development of nucleic acid-based drugs are often costly and time-consuming. The need for extensive preclinical and clinical trials, as well as the complexities of delivery systems and gene editing technologies, contribute to high development costs. This can be a significant barrier for smaller biotechnology companies and startups looking to enter the market.

• Safety concerns and regulatory hurdles

Nucleic acid-based therapies can have unique safety concerns, such as off-target effects and immune responses. These safety issues may pose challenges in gaining regulatory approvals and market acceptance. Regulatory agencies often have strict requirements for the safety and efficacy of novel therapies, which can delay market entry.

Challenges

• Delivery system complexity

Efficient and targeted delivery of nucleic acids to specific cells or tissues in the body is a complex challenge. Developing delivery systems that can protect the therapeutic nucleic acids, facilitate their entry into target cells, and avoid degradation is a major obstacle. Overcoming this challenge is crucial for the success of nucleic acid-based drugs.

• Immunogenicity and safety concerns

Nucleic acid-based drugs, especially gene therapies, can trigger immune responses or have off-target effects. Ensuring the safety and minimizing adverse reactions is a significant challenge. Researchers and developers must work to enhance the safety profiles of these therapies to gain regulatory approvals and patient trust. 

This nucleic acid based drugs market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the nucleic acid based drugs market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Development

• In March 2023, Ionis Pharmaceutical received a unanimous vote from the Food and Drug Administration (FDA) advisory committee for the potential accelerated approval of Tofersen for SOD1-ALS. Tofersen is an antisense oligonucleotide that mediates the degradation of superoxide dismutase 1 (SOD1) messenger RNA to reduce SOD1 protein synthesis
• In February 2023, Myeloid Therapeutics Inc. collaborated with New South Wales (NSW) Government in Australia to develop a state-of-the-art GMP manufacturing facility focused on RNA immunotherapies. The new facility would accelerate the commercialization of Myceloid's RNA therapeutics and the construction of an RNA ecosystem in the NSW

Global Nucleic Acid Based Drugs Market Scope

The Nucleic Acid Based Drugs market is segmented on the basis of category, structure, target, mechanism, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Category

• Antisense
• SiRNA
• MiRNA
• Aptamer
• Decoy
• CpG-oilgo

Structure

• Single Stranded DNA/RNA
• Double Stranded DNA
• Single-Stranded DNA
• Others

Target

• Transcriptor Factor
• TLR9-Receptor
• Protein

Mechanism

• Inhibits the Physiological Effect
• Adjuvant
• Inhibits Transcription
• Others

End-Users

• Hospitals
• Specialty Clinics
• Homecare
• Others

Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Others

Nucleic Acid Based Drugs Market Regional Analysis/Insights

The nucleic acid based drugs market is analysed and market size insights and trends are provided by country, category, structure, target, mechanism, end-users and distribution channel as referenced above.

Os países abrangidos no relatório de mercado são os EUA, Canadá, México, Alemanha, Reino Unido, Itália, França, Espanha, Rússia, Turquia, Suíça, Bélgica, Países Baixos, Dinamarca, Suécia, Polónia, Turquia, resto da Europa, Japão, China , Coreia do Sul, Índia, Austrália, Singapura, Japão, Tailândia, Indonésia, Nova Zelândia, Vietname, Tailândia, Indonésia, Malásia, Filipinas, resto da Ásia-Pacífico, África do Sul, Kuwait, Qatar, Omã, Arábia Saudita, Emirados Árabes Unidos e resto do Médio Oriente e África, Brasil, Argentina e resto da América do Sul.

Espera-se que a América do Norte domine o mercado dos medicamentos à base de ácidos nucleicos em termos de quota de mercado e receitas de mercado e continuará a florescer o seu domínio durante o período de previsão. Isto deve-se à presença dos principais players e o aumento dos gastos com a saúde irá impulsionar ainda mais a taxa de crescimento do mercado nesta região. Além disso, o aumento das atividades de investigação e desenvolvimento impulsionará ainda mais a taxa de crescimento do mercado nesta região.

Prevê-se que a Ásia-Pacífico cresça durante o período de previsão de 2023-2030 devido ao crescente número de atividades de investigação e desenvolvimento nesta região. Além disso, o desenvolvimento da infra-estrutura de cuidados de saúde impulsionará ainda mais a taxa de crescimento do mercado nesta região.

A secção do país do relatório também fornece fatores individuais de impacto no mercado e alterações na regulamentação do mercado interno que impactam as tendências atuais e futuras do mercado. Pontos de dados como a análise da cadeia de valor a jusante e a montante, tendências técnicas e análise das cinco forças de Porter, estudos de caso são alguns dos indicadores utilizados para prever o cenário de mercado para países individuais. Além disso, são considerados a presença e disponibilidade de marcas globais e os desafios enfrentados devido à grande ou escassa concorrência de marcas locais e nacionais, o impacto das tarifas nacionais e das rotas comerciais, ao mesmo tempo que se fornece uma análise de previsão dos dados do país.   

Crescimento da infraestrutura de saúde Base instalada e penetração de novas tecnologias

O mercado de medicamentos à base de ácido nucleico também fornece análises de mercado detalhadas para o crescimento de cada país em despesas de saúde para equipamentos de capital, base instalada de diferentes tipos de produtos para o mercado de medicamentos à base de ácido nucleico, impacto da tecnologia utilizando curvas de linha de vida e alterações na regulamentação de saúde. Os dados estão disponíveis para o período histórico 2010-2020.

Análise do panorama competitivo e da quota de mercado dos medicamentos à base de ácidos nucleicos

O panorama competitivo do mercado de medicamentos à base de ácidos nucleicos fornece detalhes por concorrente. Os detalhes incluídos são a visão geral da empresa, finanças da empresa, receitas geradas, potencial de mercado, investimento em investigação e desenvolvimento, novas iniciativas de mercado, presença global, localizações e instalações de produção, capacidades de produção, pontos fortes e fracos da empresa , lançamento de produto, largura e amplitude do produto, aplicação domínio. Os dados acima fornecidos estão apenas relacionados com o foco das empresas relacionado com o mercado de medicamentos à base de ácidos nucleicos.

Alguns dos principais players que trabalham no mercado dos medicamentos à base de ácidos nucleicos são:

• Eli Lilly and Company (EUA)
• Wave Life Sciences Ltd. (EUA)
• (EUA)
• Imugene (Austrália)
• Terapêutica PYC (Austrália)
• Protagonist Therapeutics Inc. (EUA)
• Benitec Biopharma (Austrália)
• (EUA)
• Biomedica Medizinprodukte GmbH (Reino Unido)
• Transgene (França)
• Arrowhead Pharmaceuticals, Inc.
• Ionis Pharmaceuticals (EUA)
• (EUA)
• Moderna, Lda.
• Gotham Therapeutics (EUA)
• Sumitomo Chemical Co., Ltd. (Japão)

SKU-56487